BUZZ — Evotec up 7% in early trade after 9 — month revenue, earnings beat

* Evotec's shares are up around 7% in early Frankfurt trade after the German drug discovery company's preliminary nine-month results topped expectations * The company said on Tuesday it expected 9-month group revenues of about €465.0 million, with adjusted group EBITDA of about -€42.8 million * That compares with consensus view of €429 million for revenue and adjusted EBITDA of -€45 million, a local trader says (Reporting by Anastasiia Kozlova) ((Anastasiia.Kozlova@thomsonreuters.com)